Status:
TERMINATED
A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study will evaluate the safety and tolerability of R1507 in combination with 12 distinct standard chemotherapy drug regimens and an additional R1507 monotherapy arm in patients with advanced mali...
Eligibility Criteria
Inclusion
- adult patients, \>=18 years of age;
- malignant neoplasms;
- failed prior standard curative therapy;
- ECOG performance Status of 0 or 1;
- adequate bone marrow, hepatic and renal function;
- life expectancy greater than 8 weeks.
Exclusion
- chemotherapy within 2 weeks of start of therapy;
- prior irradiation within 4 weeks prior to start of therapy;
- prior treatment with agents targeting IGF-IR inhibition, or other investigational agents;
- major surgery or significant traumatic injury within 2 weeks prior to study start;
- patients receiving concurrent antibody or immunotherapy;
- other exclusion criteria are related to specific treatment regimens.
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
104 Patients enrolled
Trial Details
Trial ID
NCT00811993
Start Date
February 1 2009
End Date
December 1 2012
Last Update
November 2 2016
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Tucson, Arizona, United States, 85724
2
San Francisco, California, United States, 94115
3
Santa Monica, California, United States, 90025
4
Washington D.C., District of Columbia, United States, 20007